Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTIVELLA vs ALPROSTADIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of estradiol, an estrogen, and norethindrone acetate, a progestin. Estrogens act by binding to nuclear estrogen receptors (ERα and ERβ), which then interact with estrogen response elements on DNA, leading to changes in gene expression that regulate growth, differentiation, and function of female reproductive tissues and other tissues. Norethindrone acetate is a progestin that induces secretory changes in the endometrium, reducing the risk of endometrial hyperplasia and carcinoma associated with unopposed estrogen therapy.
Alprostadil is a synthetic prostaglandin E1 (PGE1) that causes vasodilation by binding to prostanoid EP receptors, increasing intracellular c AMP, and relaxing smooth muscle. It also inhibits platelet aggregation.
Treatment of moderate to severe vasomotor symptoms associated with menopause,Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with menopause,Prevention of postmenopausal osteoporosis
Treatment of erectile dysfunction (intracavernosal injection or urethral suppository),Palliative therapy to maintain patency of ductus arteriosus in neonates with congenital heart defects pending surgery (intravenous infusion)
One tablet (1 mg estradiol + 0.5 mg norethindrone acetate) orally once daily, continuously.
Initial: 20-40 mcg IV bolus over 1-2 seconds; then 30-70 mcg/min continuous IV infusion for erectile dysfunction via intracavernosal injection: 2.5-10 mcg; for patent ductus arteriosus: 0.05-0.1 mcg/kg/min continuous IV infusion.
Estradiol has a terminal half-life of approximately 12–14 hours following transdermal administration. Norethindrone has a terminal half-life of approximately 8–10 hours. The combined product achieves steady-state within 3–5 days.
5-10 minutes; rapidly metabolized in the lungs, clinical effect lasts longer due to continuous infusion.
Estradiol is metabolized primarily in the liver via CYP3A4 and other CYPs, as well as by 17β-hydroxysteroid dehydrogenase and sulfotransferases. Norethindrone acetate is metabolized in the liver, primarily via reduction and conjugation, with CYP3A4 involved in some oxidative metabolism.
Primarily metabolized via oxidation in the lungs, liver, and kidneys. Approximately 80% inactivated by 15-hydroxy dehydrogenase enzyme on first pass through the lungs.
Estradiol is primarily excreted in urine (∼50%) as glucuronide and sulfate conjugates, with ∼30% excreted in feces via biliary elimination. Norethindrone is excreted mainly in urine (∼60%) as metabolites, with ∼40% in feces.
Primarily via urine (90%) as metabolites; 10% unchanged; minimal fecal excretion.
Estradiol is ∼98% bound to sex hormone-binding globulin (SHBG) and albumin. Norethindrone is ∼95–97% bound to SHBG and albumin.
80-90% bound to albumin.
Estradiol has an apparent volume of distribution (Vd) of approximately 1.2 L/kg, indicating extensive distribution into tissues. Norethindrone has a Vd of approximately 3–5 L/kg, indicating wide distribution.
0.3-0.4 L/kg (large, extensive tissue distribution).
Transdermal estradiol has a bioavailability of approximately 10% relative to oral administration due to avoidance of first-pass metabolism. Oral norethindrone acetate has a bioavailability of approximately 50–60%.
IV: 100%; intracavernosal: nearly complete; intra-arterial: high first-pass lung metabolism limits systemic bioavailability.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min); use contraindicated.
No specific GFR-based dose modifications established; use with caution in renal impairment due to potential for hypotension.
Contraindicated in severe hepatic disease (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), use caution and monitor; no specific dose adjustment established.
No specific Child-Pugh based dose modifications established; use with caution in hepatic impairment due to altered metabolism.
Not indicated for use in pediatric patients; safety and efficacy not established.
For patent ductus arteriosus: initial IV infusion 0.05-0.1 mcg/kg/min; titrate to response; for erectile dysfunction: not typically used in pediatric patients.
Start with the lowest effective dose; monitor for thromboembolic events and cognitive effects. No specific dose adjustment required, but consider age-related renal and hepatic decline.
Start at lower end of dosing range (e.g., initial IV bolus 20 mcg) due to increased sensitivity and comorbidity; monitor blood pressure closely.
Estrogens increase the risk of endometrial cancer. There is an increased risk of cardiovascular events, breast cancer, and probable dementia with estrogen plus progestin therapy. Actively monitor for these events.
None.
Cardiovascular disorders: Increased risks of stroke, myocardial infarction, and venous thromboembolism (VTE).,Malignancy: Increased risk of breast cancer, endometrial cancer, and ovarian cancer.,Probable dementia: Increased risk in women aged 65 years or older.,Gallbladder disease, hypertriglyceridemia, fluid retention, hypocalcemia, and hereditary angioedema.,Retinal thrombosis: Discontinue if sudden vision loss occurs.,Laboratory tests: May alter thyroid function tests, coagulation tests, and glucose tolerance.
Risk of priapism (prolonged erection >4 hours) requiring immediate medical attention,Risk of penile fibrosis or angulation with long-term use,Use with caution in patients with bleeding disorders or on anticoagulants due to bleeding risk,Do not use in neonates with respiratory distress syndrome or persistent fetal circulation,Monitor blood pressure during intravenous use due to hypotension risk
Undiagnosed abnormal genital bleeding,Known, suspected, or history of breast cancer,Known or suspected estrogen-dependent neoplasia,Active or past history of venous thromboembolism (VTE) or arterial thromboembolism (ATE),Current or recent (within 1 year) VTE or ATE,Known thrombophilic disorders (e.g., protein C, S, or antithrombin deficiency; factor V Leiden mutation),Active or past history of arterial thromboembolic disease (e.g., stroke, MI),Known liver impairment or disease,Known or suspected pregnancy,Hypersensitivity to any component of the product
Hypersensitivity to alprostadil,Conditions predisposing to priapism (e.g., sickle cell anemia, multiple myeloma, leukemia),Penile implant or anatomical penis deformity (for erectile dysfunction formulations),Neonates with persistent fetal circulation or respiratory distress syndrome (for intravenous formulation),In women who are pregnant or breastfeeding (not indicated)
Grapefruit juice may increase estrogen levels by inhibiting CYP3A4; avoid excessive consumption. High-fat meals can increase absorption of oral estrogens; take consistently with or without food to maintain steady levels.
No known food interactions. Grapefruit may increase levels via CYP3A4 inhibition, but clinical significance is low for topical/intracavernosal use.
Pregnancy Category X. Estrogen and progestin exposure during the first trimester is associated with congenital anomalies including cardiovascular and limb defects. Use during the second and third trimesters is contraindicated due to risk of fetal genital abnormalities and potential long-term neurodevelopmental effects. Avoid in pregnancy.
Alprostadil is not indicated for use in pregnancy; systemic exposure poses risk of uterine hyperstimulation and fetal distress. No adequate human studies; animal studies show embryotoxicity. Avoid in pregnancy unless no safer alternative.
Estradiol and norethindrone acetate are excreted into breast milk. Estradiol M/P ratio approximately 0.5; norethindrone M/P ratio approximately 0.4. May reduce milk production and alter composition. Use during breastfeeding is not recommended.
No data on excretion in human milk; M/P ratio unknown. Due to short half-life and local administration, systemic absorption minimal. Use with caution in breastfeeding.
Not applicable; contraindicated in pregnancy.
No established dosing in pregnancy; contraindicated in pregnant women. No dose adjustment data available for pregnant populations.
For patients with an intact uterus, estrogen must be combined with a progestogen (norethindrone acetate) to prevent endometrial hyperplasia. Initiate at the lowest effective dose for the shortest duration. Avoid in women with active thromboembolic disease, known or suspected breast cancer, or undiagnosed abnormal genital bleeding. Consider transdermal route if oral absorption is compromised or for migraine with aura.
Alprostadil causes vasodilation via c AMP increase; watch for hypotension and priapism. For erectile dysfunction, inject into corpus cavernosum, not dorsal vein. For patent ductus arteriosus, monitor respiratory drive as apnea is common in neonates.
Take this medication exactly as prescribed; do not skip doses or stop without consulting your doctor.,Report any unusual vaginal bleeding, breast lumps, or symptoms of blood clots (e.g., leg pain, chest pain, sudden shortness of breath, vision changes) immediately.,Smoking increases the risk of cardiovascular side effects, especially in women over 35; avoid smoking while on this therapy.,This medication does not protect against sexually transmitted infections or HIV.,Regular medical check-ups, including breast exams and mammograms, are essential during therapy.
Seek immediate medical help if erection lasts more than 4 hours.,Do not use if you have a penile implant or conditions like sickle cell disease.,Avoid driving until you know how this medication affects you.,For injection, rotate injection sites and use within 24hrs of opening vial.,Report any signs of infection at injection site.
No interactions on record
"Pirfenidone, an antifibrotic agent used for idiopathic pulmonary fibrosis, may reduce the vasodilatory efficacy of alprostadil, a prostaglandin E1 analog. This interaction likely results from pirfenidone-induced downregulation of prostaglandin receptors or modulation of cyclic AMP signaling pathways, leading to diminished smooth muscle relaxation and reduced therapeutic response to alprostadil. Consequently, patients may experience suboptimal vasodilation, potentially compromising treatment for conditions like erectile dysfunction or peripheral arterial disease."
"Concomitant administration of Alprostadil, a vasodilator, and Aminosalicylic acid, a salicylate, may produce additive antiplatelet effects, increasing the risk of bleeding. Alprostadil inhibits platelet aggregation via cAMP elevation, while Aminosalicylic acid inhibits cyclooxygenase, reducing thromboxane A2 synthesis. Clinically, this may result in prolonged bleeding time, easy bruising, or hemorrhage, especially in patients with underlying coagulopathies or those on other anticoagulants."
"Loxoprofen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX) enzymes, thereby reducing the synthesis of prostaglandins. Alprostadil, a synthetic prostaglandin E1 analog, exerts its therapeutic effects through vasodilation and inhibition of platelet aggregation. The concurrent use of loxoprofen may attenuate the pharmacological activity of alprostadil by diminishing prostaglandin-mediated responses, potentially leading to reduced efficacy in conditions such as erectile dysfunction or peripheral vascular disease."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTIVELLA vs ALPROSTADIL, answered by our medical review team.
ACTIVELLA is a Estrogen/Progestin Combination that works by Combination of estradiol, an estrogen, and norethindrone acetate, a progestin. Estrogens act by binding to nuclear estrogen receptors (ERα and ERβ), which then interact with estrogen response elements on DNA, leading to changes in gene expression that regulate growth, differentiation, and function of female reproductive tissues and other tissues. Norethindrone acetate is a progestin that induces secretory changes in the endometrium, reducing the risk of endometrial hyperplasia and carcinoma associated with unopposed estrogen therapy.. ALPROSTADIL is a Prostaglandin Analog that works by Alprostadil is a synthetic prostaglandin E1 (PGE1) that causes vasodilation by binding to prostanoid EP receptors, increasing intracellular c AMP, and relaxing smooth muscle. It also inhibits platelet aggregation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTIVELLA and ALPROSTADIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTIVELLA is: One tablet (1 mg estradiol + 0.5 mg norethindrone acetate) orally once daily, continuously.. The standard adult dose of ALPROSTADIL is: Initial: 20-40 mcg IV bolus over 1-2 seconds; then 30-70 mcg/min continuous IV infusion for erectile dysfunction via intracavernosal injection: 2.5-10 mcg; for patent ductus arteriosus: 0.05-0.1 mcg/kg/min continuous IV infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTIVELLA and ALPROSTADIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTIVELLA is classified as Category C. Pregnancy Category X. Estrogen and progestin exposure during the first trimester is associated with congenital anomalies including cardiovascular and limb defects. Use during the s. ALPROSTADIL is classified as Category C. Alprostadil is not indicated for use in pregnancy; systemic exposure poses risk of uterine hyperstimulation and fetal distress. No adequate human studies; animal studies show embry. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.